Concert Pharmaceuticals Inc. (NASDAQ:CNCE) shares fell 1.2% on Friday . The company traded as low as $9.54 and last traded at $9.59, with a volume of 62,702 shares. The stock had previously closed at $9.71.

A number of brokerages have commented on CNCE. Zacks Investment Research lowered Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. Brean Capital reaffirmed a “buy” rating on shares of Concert Pharmaceuticals in a report on Monday, July 11th. Finally, Stifel Nicolaus began coverage on Concert Pharmaceuticals in a report on Friday, July 1st. They issued a “buy” rating and a $23.00 price objective on the stock. Two analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $26.43.

The company’s market capitalization is $215.16 million. The firm’s 50 day moving average price is $11.22 and its 200-day moving average price is $12.42.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its earnings results on Tuesday, August 9th. The company reported ($0.60) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.03. Analysts anticipate that Concert Pharmaceuticals Inc. will post ($2.51) earnings per share for the current year.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.